IP Verse

Ophthalmic Suspension Composition - EP3250185

The patent EP3250185 was granted to Bausch & Lomb Incorporated on Dec 5, 2018. The application was originally filed on Jan 26, 2016 under application number EP16704744A. The patent is currently recorded with a legal status of "Revoked".

EP3250185

BAUSCH & LOMB INCORPORATED
Application Number
EP16704744A
Filing Date
Jan 26, 2016
Status
Revoked
Sep 25, 2020
Grant Date
Dec 5, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

EUROPEAN OPPOSITIONSSep 5, 2019CORNISH -
BREUERSep 5, 2019BREUERADMISSIBLE
ALLERGANSep 4, 2019HOFFMANN EITLEADMISSIBLE

Patent Citations (28) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS4540930
DESCRIPTIONUS4615697
DESCRIPTIONUS4996335
DESCRIPTIONUS5192535
DESCRIPTIONUS5538721
DESCRIPTIONWO8906964
INTERNATIONAL-SEARCH-REPORTEP0659433
INTERNATIONAL-SEARCH-REPORTUS2013303502
INTERNATIONAL-SEARCH-REPORTUS2014328917
INTERNATIONAL-SEARCH-REPORTWO2004006959
INTERNATIONAL-SEARCH-REPORTWO2013043387
OPPOSITIONAU2015288643B
OPPOSITIONAU2015288643
OPPOSITIONAU2015288644B
OPPOSITIONCN101966143
OPPOSITIONEP0663208
OPPOSITIONUS2005182039
OPPOSITIONUS2010226997
OPPOSITIONUS2013303502
OPPOSITIONUS2014328917
OPPOSITIONUS7001615
OPPOSITIONUS8921337
OPPOSITIONWO2004112836
OPPOSITIONWO2013169647
OPPOSITIONWO2015105652
OPPOSITIONWO2016006701
OPPOSITIONWO2016006702
OPPOSITIONWO2016016908

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- SCHOENWALD RD; HARRIS RG; TURNER D ET AL., "Ophthalmic bioequivalence of steroid/antibiotic combination formulations", BIOPHARM DRUG DISPOS., (1987), vol. 8, pages 527 - 548-
DESCRIPTION- TANG-LIU DD; BURKE PJ., "The effect of azone on ocular levobunolol absorption: calculating the area under the curve and its standard error using tissue sampling compartments.", PHARM RES., (1988), vol. 5, pages 238 - 241-
DESCRIPTION- LIU ET AL., "Nanosuspensions of poorly soluble drugs: preparation and development by wet milling", INT. J. OF PHARM, (2011), vol. 411, no. 1-2, doi:doi:10.1016/j.ijpharm.2011.03.050, pages 215 - 222, XP055143914
OPPOSITION- Anonymous, "Results positive for B+L sub-micron gel formulation of loteprednol etabonate", Ophthalmology Times, (20140930), URL: https://www.ophthalmologytimes.com/modern-medicine-feature-articles/results-positive-bl-sub-micron-gel-formulation-loteprednol-etabonate, XP055639922-
OPPOSITION- CAVET et al, "Ocular pharmacokinetics of submicron loteprednol etabonate ophthalmic gel, 0.38% following topical administration in rabbits", ARVO Annual Meeting Abstract, (20150600), URL: https://iovs.arvojournals.org/article.aspx?articleid=2331235&resultClick=1, XP055643069-
OPPOSITION- HUICHAO et al, "The application of biomedical polymer material hydroxy propyl methyl cellulose(HPMC) in pharmaceutical preparations", Journal of Chemical and Pharmaceutical Research, (20140000), vol. 6, no. 5, pages 155 - 160, XP055643076-
OPPOSITION- LAKSHMI et al, "NANO­-SUSPENSION TECHNOLOGY: A REVIEW", International Journal of Pharmacy and Pharmaceutical Sciences, (2010), vol. 2, no. suppl.4, pages 35 - 40, XP055643057-
OPPOSITION- MEMON, "Optimization of Formulation Parameters on Ocular Loteprednol 2012 Etabonate Nanosuspension by Media Milling Method", INTERNATIONAL JOURNAL OF PHARMACEUTICAL & BIOLOGICAL ARCHIVES, vol. 4, no. 1, pages 46 - 51, XP055643061-
OPPOSITION- OGAWA et al., "Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD", Bone Marrow Transplant., (20100000), vol. 45, pages 565 - 569, XP055639881-
OPPOSITION- RAJORIA, "In-Situ Gelling System: A Novel Approach for Ocular Drug Delivery", Am. J. PharmTech Res., (20120000), vol. 2, no. 4, XP055643055-
OPPOSITION- Rowe R C; SHESKEY P J; OWEN S C, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, 5th Edition, Pharmaceutical Press, London, UK, (2006), pages 111-115, 120-123, 346-349, 462 - 465, XP055639911-
OPPOSITION- V. ANDONOVA et al., "Eye Drops with Nanoparticles as Drug Delivery Systems", International Journal of Pharmacy and Pharmaceutical Sciences, (20150000), vol. 7, no. 2, pages 431 - 435, XP055639889-
OPPOSITION- SCHOPF, "Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation", Ophthalmol Ther, (20140000), vol. 3, pages 63 - 72, XP055643059
OPPOSITION- NAGAI et al., "Therapeutic Effects of Gel Ointments Containing Tranilast Nanoparticles on Paw Edema in Adjuvant-Induced Arthritis Rats", Biol. Pharm. Bull., (20140000), vol. 37, no. 1, pages 96 - 104, XP055639877
OPPOSITION- COFFEY et al, "Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop", Clinical Ophthalmology, (20130212), pages 299 - 312, XP055643072
OPPOSITION- Noriaki NAGAI et al., "A New Preparation Method for Ophthalmic Drug Nanoparticles", Pharm. Anal. Acta., (20140000), vol. 5, no. 7, page 305, XP055639929

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents